Evidence map›Paper›PMID 38683407›Full record

ArticleMolecular biology reports2024

Assessing the possible association between MTHFR (rs1801133) and GPx-1 (rs1050450) polymorphisms with the risk of type 2 diabetes, diabetic neuropathy, and diabetic retinopathy.

Soheila Asadi, Zohreh Rahimi, Maryam Kohsari, Fatemeh Babajani, Mohammad Amiri, Nazanin Jalilian, Rozita Naseri, Lida Haghnazari

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Soheila AsadiDepartment of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran. sohila.asadi75@yahoo.com.
Zohreh RahimiDepartment of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Maryam KohsariDepartment of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Fatemeh BabajaniDepartment of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Mohammad AmiriDepartment of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Nazanin JalilianDepartment of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Rozita NaseriDepartment of Internal Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Lida HaghnazariDepartment of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOxidative stress in chronic hyperglycemia could injure the tissues and onset of diabetes-related complications like retinopathy and neuropathy. This study investigates the association between methylenetetrahydrofolate reductase (MTHFR) and glutathione peroxidase (GPx) genetic variants with these complications.

methodsIn this case-control study, 400 individuals, including 100 healthy subjects and 300 patients with type 2 diabetes mellitus (T2DM) in three subgroups: with retinopathy(n = 100), with neuropathy(n = 100), and without complication (n = 100) from West Iran, were studied. MTHFR (rs1801133) and GPx-1 (rs1050450) variants were identified by the PCR-RFLP method. The plasma levels of GPx activity, glutathione, malondialdehyde (MDA), total antioxidant capacity (TAC), and total oxidative stress (TOS) were measured by chemical methods.

resultsHigher BMI, TOS and MDA levels were observed in patients with neuropathy compared to other patients and controls. Diabetic patients with neuropathy had lower levels of glutathione (7.8 ± 4.5; P < 0.001), GPx activity (39.5 ± 8.5; P < 0.001), and TAC (703.1 ± 129.1; P = 0.0001) in comparison with other groups. The patients without complication and retinopathic patients had higher plasma levels of glutathione (12.2 ± 2.4; p = 0.02) and TAC (793.4 ± 124.6; P < 0.001), respectively. MTHFR TT genotype significantly correlated with lower levels of TOS (3.5 ± 1.1; P < 0.001) and OSI (0.0050 ± 0.001; P < 0.001). Subjects with the GPx-1 TT genotype had higher levels of MDA (6.8 ± 2.5; P = 0.02) and lower levels of TOS (3.7 ± 1.6; P < 0.001), which is statistically significant. TT genotype of MTHFR was associated with 3.9 fold (95% CI 1.04-4.76; P = 0.0436) increased risk of neuropathy. Also, GPx-1 CT genotype increased the risk of retinopathy [OR = 2.7 (95% CI = 1.38-5.44; P = 0.0039)].

conclusionThe MTHFR TT genotype increased the risk of neuropathy in diabetic patients significantly. The GPx-1 CT genotype is related to increased retinopathy risk among diabetic patients. Both MTHFR and Gpx-1 TT genotypes were associated with higher BMI levels.

Indexed as

Diabetes Mellitus, Type 2Diabetic NeuropathiesDiabetic RetinopathyGenetic Predisposition to DiseaseGlutathione PeroxidaseGlutathione Peroxidase GPX1Methylenetetrahydrofolate Reductase (NADPH2)AdultAgedCase-Control StudiesFemaleGenetic Association StudiesGenotypeHumansIranMaleGlutathione PeroxidaseGlutathione Peroxidase GPX1GPX1 protein, humanMalondialdehydeMethylenetetrahydrofolate Reductase (NADPH2)MTHFR protein, humanGPx-1MTHFROxidative stressType 2 diabetes mellitus

Identifiers

PMID38683407

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.